Itepekimab significantly reduced hospitalizations or emergency department visits in former smokers with moderate-to-severe COPD

K. Rabe (Grosshansdorf, Kiel, Germany), B. Celli (Boston, United States), A. Praestgaard (Cambridge, United States), M. Djandji (Cambridge, United States), X. Soler (Tarrytown, United States), R. Abdulai (Cambridge, United States), D. Lederer (Tarrytown, United States), H. Goulaouic (Chilly-Mazarin, France), M. Nivens (Tarrytown, United States), S. Siddiqui (Tarrytown, United States), J. Jacob-Nara (Bridgewater, United States), Y. Deniz (Tarrytown, United States), P. Rowe (Bridgewater, United States)

Source: International Congress 2022 – Update on clinical trials in allergy, asthma and COPD

Session: Update on clinical trials in allergy, asthma and COPD
Session type: Thematic Poster
Number: 3198

Rating:

You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
K. Rabe (Grosshansdorf, Kiel, Germany), B. Celli (Boston, United States), A. Praestgaard (Cambridge, United States), M. Djandji (Cambridge, United States), X. Soler (Tarrytown, United States), R. Abdulai (Cambridge, United States), D. Lederer (Tarrytown, United States), H. Goulaouic (Chilly-Mazarin, France), M. Nivens (Tarrytown, United States), S. Siddiqui (Tarrytown, United States), J. Jacob-Nara (Bridgewater, United States), Y. Deniz (Tarrytown, United States), P. Rowe (Bridgewater, United States). Itepekimab significantly reduced hospitalizations or emergency department visits in former smokers with moderate-to-severe COPD. 3198

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.

You must Login to comment this presentation.